Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001837607-25-000066
Filing Date
2025-08-12
Accepted
2025-08-12 16:07:29
Documents
68
Period of Report
2025-06-30

Document Format Files

Seq Description Document Type Size
1 10-Q aeon-20250630x10q.htm   iXBRL 10-Q 1680335
2 EX-31.1 aeon-20250630xex31d1.htm EX-31.1 16131
3 EX-31.2 aeon-20250630xex31d2.htm EX-31.2 16049
4 EX-32.1 aeon-20250630xex32d1.htm EX-32.1 8728
5 EX-32.2 aeon-20250630xex32d2.htm EX-32.2 8853
  Complete submission text file 0001837607-25-000066.txt   8500212

Data Files

Seq Description Document Type Size
6 EX-101.SCH aeon-20250630.xsd EX-101.SCH 62606
7 EX-101.CAL aeon-20250630_cal.xml EX-101.CAL 41291
8 EX-101.DEF aeon-20250630_def.xml EX-101.DEF 286575
9 EX-101.LAB aeon-20250630_lab.xml EX-101.LAB 498331
10 EX-101.PRE aeon-20250630_pre.xml EX-101.PRE 416442
71 EXTRACTED XBRL INSTANCE DOCUMENT aeon-20250630x10q_htm.xml XML 1742808
Mailing Address 5 PARK PLAZA SUITE 1750 IRVINE CA 92614
Business Address 5 PARK PLAZA SUITE 1750 IRVINE CA 92614 (949) 354-6499
AEON Biopharma, Inc. (Filer) CIK: 0001837607 (see all company filings)

EIN.: 853940478 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-40021 | Film No.: 251206682
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)